Differential in vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators
- PMID: 2045203
- DOI: 10.1002/ijc.2910480419
Differential in vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators
Abstract
The intrinsically Vincristine(Vcr)-resistant human kidney adenocarcinoma cell line ACHN, the human acute lymphoblastic leukemia cell line L0, its more-than-100-fold Vcr-resistant subline LI00, normal human fibroblasts and lymphocytes, also tumor cells from patients with chronic lymphocytic leukemia (CLL), acute myeloblastic leukemia (AML) and solid tumors, were compared for sensitivity to cytotoxic drugs and resistance modulators (RMs). The LI00 cells showed pronounced sensitivity to the RMs verapamil (Ver), cyclosporin A (CsA) and buthionine sulfoximine (BSO) alone as well as to cisplatinum, whereas the L0 and ACHN cells, also slowly growing fibroblasts and non-proliferating lymphocytes, were considerably less sensitive. Compared with AML cells and lymphocytes, CLL cells were more sensitive to Ver and CsA alone. The cytotoxicity of Vcr was significantly increased in the Vcr-resistant ACHN and LI00, but also in sensitive L0 cells by Ver and CsA, with smaller effects on Dox and Vp-16 toxicity. Fibroblasts and lymphocytes were generally resistant to the cytotoxic agents and RM addition had only minor effects. CLL cells were more sensitive to Dox and Vcr as compared with normal lymphocytes, with potentiation of the Vcr effect by Ver and CsA. The Vcr effect in non-proliferating Vcr-resistant cells from a malignant schwannoma was potentiated by Ver and CsA, which had no effect in cells from a kidney adenocarcinoma. We conclude that cytotoxicity of RMs alone is not dependent on the proliferation rate of tumor cells and that potentiation of cytotoxic drugs by RMs may be selective for tumor cells irrespective of their initial level and mode of drug resistance.
Similar articles
-
Pharmacological modification of multi-drug resistance (MDR) in vitro detected by a novel fluorometric microculture cytotoxicity assay. Reversal of resistance and selective cytotoxic actions of cyclosporin A and verapamil on MDR leukemia T-cells.Int J Cancer. 1990 Jul 15;46(1):67-72. doi: 10.1002/ijc.2910460114. Int J Cancer. 1990. PMID: 2194983
-
Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines.Cancer Res. 1994 Oct 15;54(20):5368-73. Cancer Res. 1994. PMID: 7923167
-
Verapamil and cyclosporin A sensitize human kidney tumor cells to vincristine in absence of membrane P-glycoprotein and without apparent changes in the cytoplasmic free Ca2+ concentration.Biosci Rep. 1990 Apr;10(2):231-7. doi: 10.1007/BF01116583. Biosci Rep. 1990. PMID: 1972632
-
Modulation of antitumour drug resistance: experimental laboratory data and results of clinical evaluation.Cancer Treat Rev. 1990 Sep;17(2-3):197-202. doi: 10.1016/0305-7372(90)90047-j. Cancer Treat Rev. 1990. PMID: 1980233 Review.
-
The potential of cyclosporin A as an anti-tumour agent.Int J Immunopharmacol. 1990;12(5):469-79. doi: 10.1016/0192-0561(90)90109-z. Int J Immunopharmacol. 1990. PMID: 2210910 Review.
Cited by
-
Doxorubicin selected multidrug-resistant small cell lung cancer cell lines characterised by elevated cytoplasmic Ca2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression.Br J Cancer. 1991 Dec;64(6):1011-8. doi: 10.1038/bjc.1991.456. Br J Cancer. 1991. PMID: 1684906 Free PMC article.
-
Activity of cyclosporins as resistance modifiers in primary cultures of human haematological and solid tumours.Br J Cancer. 1994 Jul;70(1):11-7. doi: 10.1038/bjc.1994.242. Br J Cancer. 1994. PMID: 8018519 Free PMC article.
-
RNA helicase DDX3: a novel therapeutic target in Ewing sarcoma.Oncogene. 2016 May 19;35(20):2574-83. doi: 10.1038/onc.2015.336. Epub 2015 Sep 14. Oncogene. 2016. PMID: 26364611
-
In vitro analysis of drug resistance in tumor cells from patients with acute myelocytic leukemia.Med Oncol Tumor Pharmacother. 1992;9(2):65-74. doi: 10.1007/BF02989656. Med Oncol Tumor Pharmacother. 1992. PMID: 1341718
-
Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles.Br J Cancer. 2005 Aug 22;93(4):483-92. doi: 10.1038/sj.bjc.6602699. Br J Cancer. 2005. PMID: 16012520 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources